Ewch i’r prif gynnwys
Dr Jason Webber

Dr Jason Webber

Research Fellow

+44 (0)29 2068 7306
GF16, Adeilad Tenovus, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Ar gael fel goruchwyliwr ôl-raddedig


'Exploring why some cancers are more aggressive than others'

I am a Prostate Cancer UK funded Research Fellow within the Division of Cancer & Genetics.

Research within my group focuses on the role of nanometre-sized vesicles, termed exosomes, as drivers of aggressive prostate cancer. We have previously demonstrated that cancer cell-derived exosomes can activate stromal cells, also present within the tumour microenvironment, thereby facilitating enhanced tumour growth. This function of exosomes is likely due to heparan sulphate proteoglycans (HSPGs), present on the exosome surface, which are required for exosome-mediated growth factor delivery. In addition to their functional role, such exosomal-HSPGs may serve as novel biomarkers capable of discriminating patients with aggressive forms of cancer from those with slow growing tumours.

Key words:

Exosomes, prostate cancer, stroma, heparan sulphate, proteoglycans


Career overview

  • 2014 - present: Prostate Cancer UK Research Fellow, Division of Cancer & Genetics, Cardiff University
  • July 2014: Visiting Post-Doctoral Researcher, CIC bioGUNE, Bilbao, Spain
  • 2008 - 2014: Research Associate, Division of Cancer & Genetics, Cardiff University 

Education & qualifications

  • 2009: Ph.D. Cell Biology; Institute of Nephrology, School of Medicine, Cardiff University
  • 2005: B.Sc. Biochemistry with Medical Biochemistry; School of Biosciences, Cardiff University 

Anrhydeddau a Dyfarniadau

  • Prostate Cancer UK Career Development Fellowship (~£680k) - funded from Nov 2014 to Oct 2019
  • Society for Endocrinology 2013 – Best Poster Presnetation.
  • Cancer Research Wales Travel Grant (£500) – to attend ISEV 2013 Meeting, Boston, USA.
  • Prostate Action Travel Grant (£700) – to attend ISEV 2012 Meeting, Gothenburg, Sweden.
  • Velindre NHS Trust R & D Conference 2010 – Best Oral Presentation.
  • Velindre NHS Trust R & D Conference 2009 – Best Newcomer.
  • MR2-IRG Research Day, Cardiff University 2008 – Best Oral Presentation.
  • Postgraduate Research Day, Cardiff University 2007 – Best Oral Presentation.

Aelodaethau proffesiynol

  • Founding member of the International Society for Extracellular Vesicles (2011 – present)
  • Member of the European Academy for Tumour Immunology (2016 – present)
  • Member of the UK Extracellular Vesicle Forum (2014 – present)
  • Member of the Cardiff Institute of Tissue Engineering & Repair (2006 – present)

Ymrwymiadau siarad cyhoeddus

Invited seminars

  • July 2016: Extracellular Vesices - Biology & Therapeutic Potential, Select Bio, Cambridge, UK
  • June 2014: Research Seminar Series, CIC bioGUNE, Bilbao, Spain
  • June 2012: Prostate Action - The Forum (10th Biennial Prostate Cancer Forum), Rotterdam, Netherlands
  • Feb 2012: IRDB / Oncology Spring Seminar Series, Imperial College London, UK
  • April 2011: Prostate Action - Blue Skies Research Meeting, Downing College, Cambridge, UK

Pwyllgorau ac adolygu

  • 2010 - present: Member of the Cardiff University Genetic Modification and Biological Agents Safety Committee
  • 2010 - present: Departmental Biological Safety Officer
















PhD Students

  • Vincent Yeung - Prostate cancer exosomes as markers of disease progression.

Undergraduate Teaching

  • Intercalated & BSc Medical Pharamcology: Research supervisor to lab-based projects.

Research Overview

As a member of the Exosome Biology Research Group, my research focuses on the role of cancer cell-derived exosomes in regulating mechanisms associated with tumour growth and progression. Exosomes are nanometre-sized vesicles that originate from the late endosomal pathway, and are therefore distinct from other extracellular vesicles. Not only have exosomes been shown to play an important role in cell-to-cell communication, but there is growing interest in the use of exosomes as disease biomarkers.

My specific research focuses on the role of prostate cancer exosomes in driving stromal cell differentiation. In patients with prostate cancer the prostatic stroma becomes aberrantly altered with an increased presence of cells with a myofibroblast-like phenotype. These cells are absent from normal tissues but are often associated with a fibrotic response whereby precursor cells, such as fibroblasts, undergo differentiation to become myofibroblastic. In various cancers, including prostate, the presence of myofibroblasts is associated with treatment resistant cancers and aggressive disease.

Classically myofibroblastic differentiation has been shown to occur in response to Transforming Growth Factor (TGF) beta1. We have demonstrated that exosomes can also drive differentiation in a TGFbeta1-dependent manner. The resulting myofibroblast-like phenotype is, however, distinct from that generated in response to soluble TGFbeta1. It is only through exosome-induced differentiation that we can make normal prostatic stromal cells mimic those found in disease. This difference in response is likely due to heparan sulphate proteoglycans (HSPGs) which play a key role in tethering TGFbeta1 to the exosome surface and therefore delivery to the target cell.

Funded by a Prostate Cancer UK Career Development Fellowship (2014 - 2019) I am currently investigating the role of HSPGs in exosome-driven stromal cell differentiation. In addition, I aim to determine whether exosomal-HSPGs can be used to distinguish patients with aggressive prostate cancer, therefore requiring treatment, from patients with indolent disease, for whom treatment would offer no benefit.

Specific Research Areas

  • Mechanisms regulating exosome secretion
  • Exosome-induced stromal cell differentiation.
  • The role of heparan sulphate proteoglycans in regulating exosome function.
  • Exosomes as biomarkers for prostate cancer.

Group Members

  • Dr Alexandra Shephard (Post-doctoral Research Assistant)
  • Mr Vincent Yeung (PhD Student; Primary Supervisor: Dr Aled Clayton)

Grants held in last 5 years

  • Cancer Research Wales (PhD Studentship). The role of heparan sulphate proteoglycans in exosome-mediated growth factor delivery & prostate tumour growth. £98K; 2017 - 2020 (Supervisors: Dr J Webber (PI) & Dr Aled Clayton (Co-I)).
  • Welsh Crucible. Guided by the Sun: New cross-disciplinary methods for modelling and analysis of tumour growth. £8.7K; 2017 (Co-PIs: Dr J Webber & Dr E Dunlop; Co-Is: Dr J Giansiracusa, Dr H Morgan & Prof R Errington).
  • Prostate Cancer UK - Career Development Fellowship. Exosomal heparan sulphate proteoglycans drive disease progression in patients with prostate cancer. £680K; 2014 - 2019 (PI: Dr J Webber).
  • Life Sciences Research Netwrok Wales & Cardiff University (PhD Studentship). Role of exosomes in the progression of prostate cancer. £80K; 2014 - 2017 (Supervisors: Dr A Clayton (PI) & Dr J Webber (Co-I)).
  • Prostate Cancer UK. Proteomics of human prostate cancer stroma. £44.5K; 2012 - 2014 (PI: Dr A Clayton; Co-Is: Dr J Webber & Dr I Brewis). 


Past projects